PHASE 2 STUDY OF HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS

HU23F2G 在多发性硬化症急性发作中的 2 期研究

• 批准号: 6263476
• 负责人: DORCAS JOANNE LYNN
• 金额: $ 4.86万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263476
• 关键词: clinical research; clinical trial phase I; human subject; human therapy evaluation; immunotherapy; monoclonal antibody; multiple sclerosis; neuroprotectants

The in vitro biologic activity and in vivo efficacy of Hu23F2G in a nonhuman primate model of Experimental Allergic Encephamyelitis (EAE) support a potetial application in the treatment of MS. The acute exacerbation component of MS will be studied under this protocol. The rationale is that the EAE model is associated with acute onset of neurologic deficits and new lesions in the CNS, events that are analogous to the acute MS exacerbation.

Hu23F2G在实验性变态反应性脑炎（EAE）的非人灵长类动物模型中的体外生物活性和体内功效支持在MS治疗中的潜在应用。MS的急性加重组分将在该方案下进行研究。 基本原理是EAE模型与神经功能缺损急性发作和CNS新发病变相关，这些事件类似于MS急性加重。